IL158794A0 - The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetes - Google Patents

The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetes

Info

Publication number
IL158794A0
IL158794A0 IL15879402A IL15879402A IL158794A0 IL 158794 A0 IL158794 A0 IL 158794A0 IL 15879402 A IL15879402 A IL 15879402A IL 15879402 A IL15879402 A IL 15879402A IL 158794 A0 IL158794 A0 IL 158794A0
Authority
IL
Israel
Prior art keywords
adenosine
analogues
diabetes
treatment
insulin resistance
Prior art date
Application number
IL15879402A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL158794A0 publication Critical patent/IL158794A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL15879402A 2001-05-14 2002-05-14 The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetes IL158794A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111651A EP1258247A1 (en) 2001-05-14 2001-05-14 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
PCT/EP2002/005301 WO2002092093A1 (en) 2001-05-14 2002-05-14 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes

Publications (1)

Publication Number Publication Date
IL158794A0 true IL158794A0 (en) 2004-05-12

Family

ID=8177414

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15879402A IL158794A0 (en) 2001-05-14 2002-05-14 The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetes

Country Status (23)

Country Link
US (1) US20030176390A1 (xx)
EP (2) EP1258247A1 (xx)
JP (1) JP2004533448A (xx)
KR (1) KR20040002962A (xx)
CN (1) CN1518450A (xx)
BG (1) BG108356A (xx)
BR (1) BR0209650A (xx)
CA (1) CA2447408A1 (xx)
CO (1) CO5540288A2 (xx)
CZ (1) CZ20033079A3 (xx)
EA (1) EA007253B1 (xx)
EE (1) EE200300551A (xx)
HR (1) HRP20030928A2 (xx)
HU (1) HUP0400464A3 (xx)
IL (1) IL158794A0 (xx)
MX (1) MXPA03010336A (xx)
NO (1) NO20035056D0 (xx)
NZ (1) NZ529390A (xx)
PL (1) PL364573A1 (xx)
SK (1) SK14052003A3 (xx)
WO (1) WO2002092093A1 (xx)
YU (1) YU90203A (xx)
ZA (1) ZA200308777B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
AR060607A1 (es) 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
MX2009004991A (es) * 2006-11-10 2009-05-20 Novartis Ag Derivados de monoacetato de ciclopenteno-diol.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5055569A (en) * 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
NZ529390A (en) 2006-06-30
JP2004533448A (ja) 2004-11-04
ZA200308777B (en) 2006-04-26
YU90203A (sh) 2006-08-17
KR20040002962A (ko) 2004-01-07
EP1404338A1 (en) 2004-04-07
BG108356A (bg) 2004-12-30
CA2447408A1 (en) 2002-11-21
US20030176390A1 (en) 2003-09-18
HUP0400464A2 (hu) 2004-07-28
PL364573A1 (en) 2004-12-13
BR0209650A (pt) 2004-07-13
HRP20030928A2 (en) 2005-10-31
CO5540288A2 (es) 2005-07-29
MXPA03010336A (es) 2004-03-16
WO2002092093A1 (en) 2002-11-21
EP1258247A1 (en) 2002-11-20
EA200301231A1 (ru) 2004-04-29
CZ20033079A3 (cs) 2004-08-18
EE200300551A (et) 2004-02-16
CN1518450A (zh) 2004-08-04
EA007253B1 (ru) 2006-08-25
HUP0400464A3 (en) 2007-03-28
SK14052003A3 (sk) 2004-07-07
NO20035056D0 (no) 2003-11-13

Similar Documents

Publication Publication Date Title
IL161155A0 (en) Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
EP1374935A4 (en) MEDICAL SYRINGE AND METHOD FOR THE PRODUCTION THEREOF
HRP20030949A2 (en) Pulmonary administration of chemically modified insulin
HK1087337A1 (en) Use of a hif-alpha stabilizing agent for the preparation of medicament for treatment of diabetes
HK1064090A1 (en) Xanthine derivative, production and use thereof asa medicament
IL158794A0 (en) The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetes
HK1045111B (zh) 用於治療胰島素的抗阻和二型糖尿病之(3-三鹵代甲基苯氧基) (4-鹵代苯基) ((3-trihalo-methylphenoxy)(4-halophenyl))
MXPA03004936A (es) Compuestos ciclicos fusionados y uso medicinal de los mismos.
HK1134077A1 (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments 8-[3---1-]-
HK1046240A1 (en) Pharmaceutical compositions for the treatment of insulin resistance
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
EP1575582A4 (en) COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME
AU2003255612A8 (en) Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments
IL165213A0 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilizationmedicament or diagnostic agent and medicament containing same
EP1436323A4 (en) CRYSTALLINE STRUCTURE OF BAFF AND USE FOR THE DESIGN OF MEDICAMENTS
AU2003272260A8 (en) Verifiable absorption drug delivery form based on cyclodextrins
IL173918A0 (en) Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicaments comprising the same
HUP0303597A3 (en) Diposable vaginal cannula for the simultaneous administration of drugs in different forms
IL162507A (en) Use of ifnar2 mutants in the manufacture of medicaments
AU2003294952A8 (en) 3,3-dimethyl-8-oxoisoquinolines for medical purposes, methods for the production thereof, medicaments containing said compounds and the use of the same
GB0117134D0 (en) Treatment of the insulin resistance syndrome
GB0024093D0 (en) Treatment of the insulin resistance syndrome
GB0030649D0 (en) Treatment of the insulin resistance syndrome
ZA200301030B (en) Treatment of the insulin resistance syndrome.
SI1465641T1 (sl) Zdravila, ki vsebujejo devterij, za zdravljenje sladkorne bolezni